The 1st International Electronic Conference on Vaccines
RNA Vaccines, Current Challenges and Future Developments
the chairs
mRNA vaccines have been developed and trialled for cancers and infectious diseases. Although the success of mRNA vaccines has been achieved in the control of COVID-19, there are challenges for future development. The production of mRNA vaccines requires multiple steps including mRNA synthesis, purification, and formulation with, e.g., lipid nanoparticles. Therefore, the stability of intermediate and final products during storage and transportation is a real problem. Breakthrough infections of SARS-CoV-2 variants and the immune evasion of cancers driven by the mutation of antigens expressed from mRNA are the major challenges in development. Since mRNA vaccines have shown advantages compared to others due to the induction of humoral and cellular immune responses and adaptability in viral and tumour antigens, future vaccines should be stabler, safer, and more compatible with other regimens in combination with other options.
All vaccine-related scientists or researchers are welcome to join this event and share their findings around the following general and related themes including but not limited to:
- Vaccines to counter anti-microbial resistance;
- Vaccines to eradicate endemic disease-opportunities and challenges;
- Vaccines to prevent zoonotic transmission-targeting the animal reservoir;
- Vaccine platforms—advantages and disadvantages;
- Clinical trial design for reactive and preventive vaccination;
- Vaccine deployment in outbreak settings—lessons learned;
- Advances in vaccine formulation and adjuvantisation;
- Clinical view on routinisation of RNA vaccines;
- How do we prepare for vaccines against the as yet unknown?;
- COVID-19 Vaccine Hesitancy;
- Immune Response after Vaccination against SARS-CoV-2 in Patients with Chronic Diseases;
- T Cell Responses in SARS-CoV-2;
- SARS-CoV-2 Variant and Vaccines Development;
- Novel Technology and Vaccines Development for COVID-19;
- T Cell Immunity and HIV-1 Pathogenicity;
- Neurological Complications Following COVID-19 Infection and COVID-19 Vaccination;
- Vaccine hesitancy;
- Vaccine safety;
- Vaccine ingredients;
- Vaccine schedule;
- Vaccine objections;
- Vaccines influence on education;
- Cost-Effectiveness of vaccines;
- Vaccine transportation;
- Methods of Vaccination;
- Vaccine-related policy.
Prof. Dr. François Meurens
Dr. Fanny Renois
The Chair of the 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments
Meet Our Chairs
Swine and Poultry Infectious Diseases Research Center (CRIPA), Faculty of Veterinary Medicine, University of Montreal, Canada;François Meurens a réalisé ses études de médecine vétérinaire en Belgique (Université Catholique de Louvain et Université de Liège) où il a obtenu son diplôme en 2000. En 2001, il a obtenu sa maîtrise en Sciences Vétérinaires (orientation virologie) et en 2004 il a terminé sa thèse de doctorat en Sciences Vétérinaires après avoir étudié la recombinaison génétique chez les alphaherpèsvirus de ruminants (Laboratoire du Professeur Etienne Thiry). Ensuite il a effectué un post-doctorat à VIDO-InterVac à l’Université de la Saskatchewan (Canada) pendant deux ans. Là-bas il s’est intéressé à l’immunologie des muqueuses dans les espèces porcine et ovine (laboratoire du Pr Volker Gerdts). Fin 2006 il a intégré l’INRA de Tours (unité ISP) en qualité de chargé de recherche. Sur place il a animé une équipe spécialisée dans l’étude des relations hôte/pathogène dans le modèle porcin. En 2012 il a ensuite accepté un poste de Scientique/Professeur adjoint à VIDO-InterVac (Canada) où il a animé une équipe sur des thématiques très similaires à celles développées en France. Une attention particulière a été portée à l’intérêt du porc en tant qu’espèce modèle pour la recherche biomédicale humaine. Auteurs de nombreuses publications dans des journaux internationaux à comité de lecture et exerçant des activités d’experts pour le secteur privé et dans les comités éditoriaux des revues Veterinary Immunology and Immunopathology et Frontiers in Veterinary Medicine, le Dr Meurens s’est orienté en 2015 vers une carrière plus académique alliant l’enseignement à la recherche scientifique à Oniris. Depuis lors il exerce son activité d’enseignement en microbiologie/immunologie et son activité de recherche au sein de l’UMR BioEpAR.
INRAE, Oniris, BIOEPAR, France;Short biography Fanny Renois (PhD, HDR) began her career as an immuno-virologist at the Faculty of Medicine and the University Hospital of Reims (France). Her first project focused on Picornaviridae with respiratory tropism in humans, which were awarded the RICAI Prize in 2012. Then, Fanny Renois developed her research on the elucidation of the role of Coxsackieviruses and their mechanism of action in the development of dilated cardiomyopathies and sudden death in young adults. Since 2016, Fanny Renois has been an associate professor of public health at the National Veterinary School of Nantes (France). Currently, she is developing research to understand the molecular aspects of the innate immune response developed against multiple respiratory viruses in the porcine species.
Important Dates
15 Sep
2023 (23:59 AoE)
27 Sep
2023 (23:59 AoE)
20 Oct
2023 (23:59 AoE)
Meet Our Speaker
Science Department, University College Roosevelt, Middelburg, The Netherlands; St. Elisabeth Hospital, Tilburg, The Netherlands;
During the duration of the conference, TWO live online sessions will be programmed. The live streaming platform we are using is Zoom. During each session, the participants will have the possibility to ask questions during a Q&A session. Detailed information about the topics and dates will be shared soon.
The live sessions are free of charge. The authors who submit submissions to IECV 2023 will have priority for the registration (with no extra cost) to the live online sessions with our keynote speakers. If it is not completely full, registration will be open for unregistered participants. Registrations with academic institutional email addresses will be prioritized. The number of participants in the live session is limited but the recording will be made available on Sciforum shortly afterward.
We are pleased to invite you to subscribe to our conference so that you can receive email notifications when the live session program is online and open online discussions.
|
CET |
EST |
CST Asia |
Speaker |
|
09:00 - 09:10 |
3:00-3:10 | 16:00-16:10 | Prof. Dr. Silvio Tafuri Welcome message |
|
09:10 - 09:40 |
3:10-3:40 | 16:10-16:40 |
Prof. Dr. Silvio Tafuri and Dr. Antonio Di Lorenzo |
|
09:40 - 10:10 |
3:40-4:10 | 16:40-17:10 | Prof. Dr. Hidehiro Fukuyama Transdermal adjuvant for next-generation vaccines |
|
10:10 - 10:40 |
4:10-4:40 | 17:10-17:40 |
Prof. Dr. S. Louise Cosby |
|
CET |
EST |
CST Asia |
Speaker |
|
14:00-14:10 |
8:00-8:10 | 21:00-21:10 | Prof. Dr. François Meurens Welcome message |
|
14:10-14:40 |
8:10-8:40 | 21:10-21:40 |
Prof. Dr. Ger Rijkers |
|
14:40-15:10 |
8:40-9:10 | 21:40-22:10 | Prof. Dr. Ranjit Ray Modified envelope glycoproteins and the use of mRNA-LNP platform as hepatitis C virus candidate vaccine |
|
15:10-15:40 |
9:10-9:40 | 22:10-22:40 | Prof. Dr. Vishwanath Venketaraman g\Glutathione improves host immune responses against Mycobacterium tuberculosis infection |
Live Session 1 (1 December 2023)
Live Session 2 (4 December 2023)
Ms. Cynthia Wang
Ms. Alethea Liu
For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.
E-Mail: iecv@mdpi.com